Edwards Lifesciences (NYSE:EW) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Edwards Lifesciences (NYSE:EW) from a hold rating to a buy rating in a report issued on Saturday morning,Wall Street Zen reports.

Other research analysts have also recently issued research reports about the stock. Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Citigroup reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Monday, October 5th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. UBS Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Thursday, October 8th. Finally, Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

NYSE EW opened at $87.32 on Friday. The company has a 50-day moving average price of $88.35 and a 200-day moving average price of $86.43. Edwards Lifesciences has a 52 week low of $74.43 and a 52 week high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $50.28 billion, a P/E ratio of 30.82, a PEG ratio of 2.27 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Annette Brüls sold 2,644 shares of the firm’s stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This trade represents a 12.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $85.65, for a total transaction of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,428,912.10. This represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 5,045 shares of company stock valued at $451,596. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in Edwards Lifesciences in the second quarter worth about $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at about $1,274,082,000. Bank of America Corp DE purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $605,397,000. Deutsche Bank AG purchased a new stake in Edwards Lifesciences during the second quarter valued at approximately $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Edwards Lifesciences by 0.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after acquiring an additional 30,495 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.